{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:19:24Z","timestamp":1792639164522,"version":"4.5.0"},"reference-count":186,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s13311-022-01261-4","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T15:02:46Z","timestamp":1657033366000},"page":"1782-1798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Leptomeningeal Metastases: New Opportunities in the Modern Era"],"prefix":"10.1016","volume":"19","author":[{"given":"Jessica A.","family":"Wilcox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9029-1248","authenticated-orcid":false,"given":"Adrienne A.","family":"Boire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1007\/s13311-022-01261-4_bib1","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/neuonc\/noaa298","article-title":"Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors","volume":"23","author":"Le Rhun","year":"2021","journal-title":"Neuro Oncol"},{"issue":"18","key":"10.1007\/s13311-022-01261-4_bib2","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1212\/WNL.0b013e3181dc1a69","article-title":"Leptomeningeal metastases in the MRI era","volume":"74","author":"Clarke","year":"2010","journal-title":"Neurology"},{"issue":"6","key":"10.1007\/s13311-022-01261-4_bib3","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.cell.2017.02.025","article-title":"Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis","volume":"168","author":"Boire","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/1097-0142(19830101)51:1<154::AID-CNCR2820510130>3.0.CO;2-K","article-title":"Leptomeningeal carcinomatosis. How does cancer reach the pia-arachnoid?","volume":"51","author":"Kokkoris","year":"1983","journal-title":"Cancer"},{"issue":"7716","key":"10.1007\/s13311-022-01261-4_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41586-018-0342-5","article-title":"Leukaemia hijacks a neural mechanism to invade the central nervous system","volume":"560","author":"Yao","year":"2018","journal-title":"Nature"},{"key":"10.1007\/s13311-022-01261-4_bib6","article-title":"Leptomeningeal metastatic cells adopt two phenotypic states.","author":"Remsik","year":"2020","journal-title":"Cancer Rep."},{"issue":"suppl_4","key":"10.1007\/s13311-022-01261-4_bib7","doi-asserted-by":"crossref","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","volume":"28","author":"Le Rhun","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1007\/s13311-022-01261-4_bib8","first-page":"484","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2016","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1007\/s13311-022-01261-4_bib9","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0733-8619(18)31006-5","article-title":"Neurologic complications of systemic cancer","volume":"3","author":"Patchell","year":"1985","journal-title":"Neurol Clin"},{"issue":"4","key":"10.1007\/s13311-022-01261-4_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/07357900009012181","article-title":"Diagnostic evaluation of neurologic metastases","volume":"18","author":"Jeyapalan","year":"2000","journal-title":"Cancer Invest"},{"issue":"20","key":"10.1007\/s13311-022-01261-4_bib11","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1212\/01.wnl.0000407892.25373.7b","article-title":"Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology","volume":"77","author":"Glass","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0733-8619(02)00032-4","article-title":"Leptomeningeal metastases","volume":"21","author":"Kesari","year":"2003","journal-title":"Neurol Clin"},{"issue":"4","key":"10.1007\/s13311-022-01261-4_bib13","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO;2-Z","article-title":"Cerebrospinal fluid cytology in patients with cancer","volume":"82","author":"Glantz","year":"1998","journal-title":"Cancer"},{"issue":"3","key":"10.1007\/s13311-022-01261-4_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11060-021-03827-2","article-title":"Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes","volume":"154","author":"Bander","year":"2021","journal-title":"J Neurooncol"},{"issue":"3","key":"10.1007\/s13311-022-01261-4_bib15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JCO.1993.11.3.561","article-title":"Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis Eastern Cooperative Oncology Group","volume":"11","author":"Grossman","year":"1993","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1007\/s13311-022-01261-4_bib16","first-page":"3394","article-title":"A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors","volume":"5","author":"Glantz","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1007\/s13311-022-01261-4_bib17","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1200\/JCO.1987.5.10.1655","article-title":"A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis","volume":"5","author":"Hitchins","year":"1987","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1007\/s13311-022-01261-4_bib18","first-page":"885","article-title":"Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study","volume":"61","author":"Gutin","year":"1977","journal-title":"Cancer Treat Rep"},{"issue":"2","key":"10.1007\/s13311-022-01261-4_bib19","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1215\/15228517-2007-059","article-title":"A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies","volume":"10","author":"Groves","year":"2008","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1007\/s13311-022-01261-4_bib20","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/neuonc\/noz201","article-title":"Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer","volume":"22","author":"Le Rhun","year":"2020","journal-title":"Neuro Oncol"},{"issue":"18","key":"10.1007\/s13311-022-01261-4_bib21","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1016\/j.ejca.2004.08.012","article-title":"The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study","volume":"40","author":"Boogerd","year":"2004","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1007\/s13311-022-01261-4_bib22","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1764::AID-CNCR24>3.0.CO;2-1","article-title":"Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy","volume":"82","author":"Bokstein","year":"1998","journal-title":"Cancer"},{"issue":"3","key":"10.1007\/s13311-022-01261-4_bib23","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40262-015-0319-6","article-title":"Pharmacokinetic properties of anticancer agents for the treatment of central nervous system tumors: update of the literature","volume":"55","author":"Jacus","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1007\/s13311-022-01261-4_bib24","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1007\/s13311-022-01261-4_bib25","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s43018-021-00198-5","article-title":"Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations","volume":"2","author":"Brastianos","year":"2021","journal-title":"Nature Cancer"},{"issue":"10","key":"10.1007\/s13311-022-01261-4_bib26","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/s41419-021-04223-4","article-title":"Genomic comparison between cerebrospinal fluid and primary tumor revealed the genetic events associated with brain metastasis in lung adenocarcinoma","volume":"12","author":"Deng","year":"2021","journal-title":"Cell Death Dis"},{"issue":"4","key":"10.1007\/s13311-022-01261-4_bib27","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/annonc\/mdy009","article-title":"Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy","volume":"29","author":"Li","year":"2018","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1007\/s13311-022-01261-4_bib28","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1158\/1078-0432.CCR-19-2840","article-title":"Proteomic analysis of CSF from patients with leptomeningeal melanoma metastases identifies signatures associated with disease progression and therapeutic resistance","volume":"26","author":"Smalley","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1007\/s13311-022-01261-4_bib29","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.6004\/jnccn.2020.0052","article-title":"central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Nabors","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1007\/s13311-022-01261-4_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00641","article-title":"Palliative radiotherapy for leptomeningeal carcinomatosis\u2013analysis of outcome, prognostic factors, and symptom response","volume":"8","author":"El Shafie","year":"2019","journal-title":"Front Oncol"},{"key":"10.1007\/s13311-022-01261-4_bib31","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3389\/fonc.2019.01224","article-title":"Radiotherapy in leptomeningeal disease: a systematic review of randomized and non-randomized trials","volume":"9","author":"Buszek","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ctrv.2008.09.002","article-title":"Pediatric medulloblastoma: toxicity of current treatment and potential role of protontherapy","volume":"35","author":"Fossati","year":"2009","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib33","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s12885-020-06984-1","article-title":"Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting","volume":"20","author":"Devecka","year":"2020","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1007\/s13311-022-01261-4_bib34","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijrobp.2013.01.014","article-title":"Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma","volume":"86","author":"Brown","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib35","doi-asserted-by":"crossref","first-page":"E625","DOI":"10.1016\/j.ijrobp.2019.06.1163","article-title":"A comparison of acute toxicities between vertebral-body-sparing proton craniospinal irradiation and standard photon CSI in pediatric patients","volume":"105","author":"Hopper","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/neuonc\/noaa152","article-title":"Clinical trial of proton craniospinal irradiation for leptomeningeal metastases","volume":"23","author":"Yang","year":"2021","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1007\/s13311-022-01261-4_bib37","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1007\/s13311-022-01261-4_bib38","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1007\/s13311-022-01261-4_bib39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.lungcan.2017.12.008","article-title":"Intracerebral efficacy and tolerance of nivolumab in non\u2013small-cell lung cancer patients with brain metastases","volume":"116","author":"Gauvain","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1007\/s13311-022-01261-4_bib40","article-title":"The effect of asymptomatic and\/or treated brain metastases on efficacy of immune checkpoint inhibitors in metastatic non\u2013small cell lung cancer: a meta-analysis.","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol."},{"issue":"10","key":"10.1007\/s13311-022-01261-4_bib41","doi-asserted-by":"crossref","first-page":"S863","DOI":"10.1016\/j.jtho.2021.08.062","article-title":"OA09.02 Atezo-Brain: single arm phase II study of atezolizumab plus chemotherapy in stage IV NSCLC with untreated brain metastases","volume":"16","author":"Nadal","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1007\/s13311-022-01261-4_bib42","doi-asserted-by":"crossref","DOI":"10.1097\/COC.0000000000000849","article-title":"Outcomes of stereotactic radiosurgery and immunotherapy in renal cell carcinoma patients with brain metastases.","volume":"44","author":"Uezono","year":"2021","journal-title":"Am J Clin Oncol."},{"issue":"23","key":"10.1007\/s13311-022-01261-4_bib43","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.18.02218","article-title":"Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study","volume":"37","author":"Flippot","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1007\/s13311-022-01261-4_bib44","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/JCO.2021.39.15_suppl.4515","article-title":"Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial","volume":"39","author":"Emamekhoo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1007\/s13311-022-01261-4_bib45","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib46","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41416-020-01175-y","article-title":"Treatment strategies for breast cancer brain metastases","volume":"124","author":"Bailleux","year":"2021","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1007\/s13311-022-01261-4_bib47","doi-asserted-by":"crossref","first-page":"e0150945","DOI":"10.1371\/journal.pone.0150945","article-title":"T-lymphocytes traffic into the brain across the blood-CSF barrier: evidence using a reconstituted choroid plexus epithelium","volume":"11","author":"Strazielle","year":"2016","journal-title":"PLoS ONE"},{"issue":"14","key":"10.1007\/s13311-022-01261-4_bib48","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1158\/1078-0432.CCR-21-1694","article-title":"Single-cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases","volume":"27","author":"Smalley","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"13 Supplement","key":"10.1007\/s13311-022-01261-4_bib49","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/1538-7445.AM2021-1751","article-title":"Abstract 1751: Decoding the immune system response to leptomeningeal metastasis","volume":"81","author":"Remsik","year":"2021","journal-title":"Can Res"},{"issue":"8","key":"10.1007\/s13311-022-01261-4_bib50","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-020-0918-0","article-title":"Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis","volume":"26","author":"Brastianos","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib51","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.1038\/s41467-021-25859-y","article-title":"Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis","volume":"12","author":"Brastianos","year":"2021","journal-title":"Nat Commun"},{"issue":"8","key":"10.1007\/s13311-022-01261-4_bib52","doi-asserted-by":"crossref","first-page":"e002473","DOI":"10.1136\/jitc-2021-002473","article-title":"Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers","volume":"9","author":"Naidoo","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib53","article-title":"Combination of atezolizumab, bevacizumab, and chemotherapy (IMpower 150) in a patient with NSCLC having leptomeningeal metastases.","volume":"2","author":"Remon","year":"2021","journal-title":"JTO Clin Res Rep."},{"key":"10.1007\/s13311-022-01261-4_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00819","article-title":"Dramatic response of leptomeningeal carcinomatosis to nivolumab in PD-L1 highly expressive non-small cell lung cancer: a case report","volume":"9","author":"Arias Ron","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib55","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1038\/s41467-021-25860-5","article-title":"Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases","volume":"12","author":"Prakadan","year":"2021","journal-title":"Nat Commun"},{"issue":"Supplement_3","key":"10.1007\/s13311-022-01261-4_bib56","doi-asserted-by":"crossref","first-page":"iii8","DOI":"10.1093\/noajnl\/vdab071.030","article-title":"LMD-05. Phase 1B study of avelumab and whole brain radiotherapy (WBRT) in patients with leptomeningeal disease (LMD): preliminary results","volume":"3","author":"Pina","year":"2021","journal-title":"Neuro-Oncol Adv"},{"issue":"17","key":"10.1007\/s13311-022-01261-4_bib57","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib58","doi-asserted-by":"crossref","first-page":"e000283","DOI":"10.1136\/esmoopen-2017-000283","article-title":"Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2","volume":"3","author":"Glitza","year":"2018","journal-title":"ESMO Open"},{"issue":"2","key":"10.1007\/s13311-022-01261-4_bib59","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11060-017-2590-x","article-title":"High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases","volume":"135","author":"Ge","year":"2017","journal-title":"J Neurooncol"},{"issue":"11","key":"10.1007\/s13311-022-01261-4_bib60","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","article-title":"Leptomeningeal metastases in patients with NSCLC with EGFR mutations","volume":"11","author":"Li","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1007\/s13311-022-01261-4_bib61","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/JTO.0b013e318294c8e8","article-title":"Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer","volume":"8","author":"Lee","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1007\/s13311-022-01261-4_bib62","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.18632\/oncotarget.2886","article-title":"A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer","volume":"6","author":"Jackman","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1007\/s13311-022-01261-4_bib63","first-page":"4177","article-title":"Cerebrospinal fluid penetration rate and efficacy of afatinib in patients with EGFR mutation-positive non-small cell lung cancer with leptomeningeal carcinomatosis: a multicenter prospective study","volume":"37","author":"Tamiya","year":"2017","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1007\/s13311-022-01261-4_bib64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1007\/s13311-022-01261-4_bib65","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jtho.2019.12.113","article-title":"Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis","volume":"15","author":"Ahn","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1007\/s13311-022-01261-4_bib66","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1007\/s13311-022-01261-4_bib67","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.annonc.2020.06.017","article-title":"A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy","volume":"31","author":"Park","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib68","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/bjc.2017.394","article-title":"Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer","volume":"118","author":"Nanjo","year":"2018","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1007\/s13311-022-01261-4_bib69","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"issue":"30","key":"10.1007\/s13311-022-01261-4_bib70","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1007\/s13311-022-01261-4_bib71","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1007\/s13311-022-01261-4_bib72","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14\u2013mutated or MET-amplified non\u2013small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1007\/s13311-022-01261-4_bib73","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non\u2013small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1007\/s13311-022-01261-4_bib74","first-page":"100072","article-title":"Leptomeningeal response to capmatinib after progression on crizotinib in a patient with MET exon 14-mutant NSCLC","volume":"1","author":"Cravero","year":"2020","journal-title":"JTO Clin Res Rep"},{"issue":"3","key":"10.1007\/s13311-022-01261-4_bib75","doi-asserted-by":"crossref","first-page":"100145","DOI":"10.1016\/j.jtocrr.2021.100145","article-title":"Lazarus response to tepotinib for leptomeningeal metastases in a patient with MET exon 14 skipping mutation\u2013positive lung adenocarcinoma: case report","volume":"2","author":"Ninomaru","year":"2021","journal-title":"JTO Clinical and Research Reports"},{"issue":"7153","key":"10.1007\/s13311-022-01261-4_bib76","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"issue":"26","key":"10.1007\/s13311-022-01261-4_bib77","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non\u2013small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1007\/s13311-022-01261-4_bib78","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1097\/JTO.0000000000000029","article-title":"Ou S-HI, Logan J, Borges LF, and Shaw AT, The central nervous system as a sanctuary site in ALK-positive non\u2013small-cell lung cancer","volume":"8","author":"Gainor","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"24","key":"10.1007\/s13311-022-01261-4_bib79","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2015.65.5936","article-title":"Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2","volume":"34","author":"Crin\u00f2","year":"2016","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1007\/s13311-022-01261-4_bib80","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2016.68.4639","article-title":"Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer","volume":"34","author":"Gadgeel","year":"2016","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1007\/s13311-022-01261-4_bib81","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1200\/JCO.2017.77.5841","article-title":"Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials","volume":"36","author":"Camidge","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1007\/s13311-022-01261-4_bib82","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib83","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11523-020-00702-4","article-title":"Brain penetration of lorlatinib: cumulative incidences of CNS and non-CNS progression with lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer","volume":"15","author":"Bauer","year":"2020","journal-title":"Target Oncol"},{"issue":"21","key":"10.1007\/s13311-022-01261-4_bib84","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1007\/s13311-022-01261-4_bib85","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1007\/s13311-022-01261-4_bib86","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.annonc.2021.02.012","article-title":"Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs","volume":"32","author":"Felip","year":"2021","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1007\/s13311-022-01261-4_bib87","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","article-title":"Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases","volume":"33","author":"Costa","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1007\/s13311-022-01261-4_bib88","doi-asserted-by":"crossref","first-page":"S382","DOI":"10.1016\/j.jtho.2018.08.379","article-title":"MA08.05 brain penetration of lorlatinib and cumulative incidence rates for CNS and non CNS progression from a phase 1\/2 study","volume":"13","author":"Bauer","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1007\/s13311-022-01261-4_bib89","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.jtho.2020.04.019","article-title":"An international real-world analysis of the efficacy and safety of lorlatinib through early or expanded access programs in patients with tyrosine kinase inhibitor\u2013refractory ALK-positive or ROS1-positive NSCLC","volume":"15","author":"Zhu","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1007\/s13311-022-01261-4_bib90","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920980558","article-title":"Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program","volume":"13","author":"Frost","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib91","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/1759-7714.13259","article-title":"Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: a case report","volume":"11","author":"Li","year":"2020","journal-title":"Thorac Cancer"},{"issue":"2","key":"10.1007\/s13311-022-01261-4_bib92","doi-asserted-by":"crossref","first-page":"100","DOI":"10.14791\/btrt.2021.9.e19","article-title":"Lorlatinib therapy for rapid and dramatic control of brain and spinal leptomeningeal metastases from ALK-positive lung adenocarcinoma","volume":"9","author":"Sun","year":"2021","journal-title":"Brain Tumor Res Treat"},{"issue":"7","key":"10.1007\/s13311-022-01261-4_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-227299","article-title":"Rapid regression of neurological symptoms in patients with metastasised ALK+ lung cancer who are treated with lorlatinib: a report of two cases.","volume":"12","author":"Gafer","year":"2019","journal-title":"BMJ Case Rep."},{"issue":"2","key":"10.1007\/s13311-022-01261-4_bib94","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3816\/CBC.2003.n.016","article-title":"Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival","volume":"4","author":"Lower","year":"2003","journal-title":"Clin Breast Cancer"},{"issue":"12","key":"10.1007\/s13311-022-01261-4_bib95","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1002\/cncr.11436","article-title":"Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma","volume":"97","author":"Bendell","year":"2003","journal-title":"Cancer"},{"issue":"suppl_6","key":"10.1007\/s13311-022-01261-4_bib96","doi-asserted-by":"crossref","first-page":"vi58","DOI":"10.1093\/neuonc\/noy148.234","article-title":"CMET-22. Intrathecal (It) Traztuzumab (T) for the treatment of leptomeningeal metastases (LM) in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) cancer: a multicenter phase 1\/2 study","volume":"20","author":"Kumthekar","year":"2018","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1007\/s13311-022-01261-4_bib97","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11060-020-03555-z","article-title":"Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer","volume":"148","author":"Malani","year":"2020","journal-title":"J Neurooncol"},{"issue":"3","key":"10.1007\/s13311-022-01261-4_bib98","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s10549-019-05170-7","article-title":"Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy","volume":"175","author":"Figura","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1007\/s13311-022-01261-4_bib99","doi-asserted-by":"crossref","first-page":"102046","DOI":"10.1016\/j.ctrv.2020.102046","article-title":"Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: a metanalysis with meta-regression","volume":"88","author":"Zagouri","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1007\/s13311-022-01261-4_bib100","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer","volume":"15","author":"Lin","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib101","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","article-title":"Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study","volume":"14","author":"Bachelot","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1007\/s13311-022-01261-4_bib102","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jnci.2014.08.001","article-title":"All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer\u2013a phase II study","volume":"26","author":"Shawky","year":"2014","journal-title":"J Egypt Natl Canc Inst"},{"issue":"13","key":"10.1007\/s13311-022-01261-4_bib103","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1200\/JCO.18.01511","article-title":"TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases","volume":"37","author":"Freedman","year":"2019","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1007\/s13311-022-01261-4_bib104","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1158\/1078-0432.CCR-18-3502","article-title":"Phase I study of intermittent high-dose lapatinib alternating with capecitabine for HER2-positive breast cancer patients with central nervous system metastases","volume":"25","author":"Morikawa","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1007\/s13311-022-01261-4_bib105","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/annonc\/mdu041","article-title":"Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases","volume":"25","author":"Gori","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1007\/s13311-022-01261-4_bib106","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clbc.2019.07.011","article-title":"Pre- and postoperative neratinib for HER2-positive breast cancer brain metastases: translational breast cancer research consortium 022","volume":"20","author":"Freedman","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1007\/s13311-022-01261-4_bib107","doi-asserted-by":"crossref","first-page":"131","DOI":"10.25259\/SNI-106-2019","article-title":"A case of leptomeningeal metastases of human epidermal growth factor receptor 2-positive breast cancer that responded well to lapatinib plus capecitabine","volume":"10","author":"Nakao","year":"2019","journal-title":"Surg Neurol Int"},{"issue":"7","key":"10.1007\/s13311-022-01261-4_bib108","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1007\/s13311-022-01261-4_bib109","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.20.00775","article-title":"Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4_Supplement","key":"10.1007\/s13311-022-01261-4_bib110","doi-asserted-by":"crossref","first-page":"PD4-02","DOI":"10.1158\/1538-7445.SABCS21-PD4-02","article-title":"Abstract PD4\u201302: safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study","volume":"82","author":"Murthy","year":"2022","journal-title":"Cancer Res"},{"issue":"15_suppl","key":"10.1007\/s13311-022-01261-4_bib111","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2021.39.15_suppl.1044","volume":"39","author":"Stringer-Reasor","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1007\/s13311-022-01261-4_bib112","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","article-title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial\u2606","volume":"31","author":"Montemurro","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib113","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/mdu486","article-title":"Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA","volume":"26","author":"Krop","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib114","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12885-018-3994-5","article-title":"Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review","volume":"18","author":"Ricciardi","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib115","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13058-021-01459-y","article-title":"Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions","volume":"23","author":"Ferraro","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"7","key":"10.1007\/s13311-022-01261-4_bib116","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01261-4_bib117","doi-asserted-by":"crossref","first-page":"S486","DOI":"10.1016\/j.annonc.2021.08.563","article-title":"280P Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: results from the first stage of the phase II TUXEDO-1 trial","volume":"32","author":"Bartsch","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1007\/s13311-022-01261-4_bib118","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/bjc.1991.147","article-title":"Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients","volume":"63","author":"Lien","year":"1991","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1007\/s13311-022-01261-4_bib119","first-page":"2175","article-title":"Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment","volume":"49","author":"Lien","year":"1989","journal-title":"Cancer Res"},{"issue":"9","key":"10.1007\/s13311-022-01261-4_bib120","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1002\/jps.23600","article-title":"Investigation of the effect of active efflux at the blood-brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system","volume":"102","author":"Miyajima","year":"2013","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1007\/s13311-022-01261-4_bib121","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1158\/1078-0432.CCR-18-1968","article-title":"Continued endocrine therapy is associated with improved survival in patients with breast cancer brain metastases","volume":"25","author":"Bergen","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1007\/s13311-022-01261-4_bib122","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jjco\/hyg046","article-title":"Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection","volume":"33","author":"Ozdogan","year":"2003","journal-title":"Jpn J Clin Oncol"},{"issue":"8","key":"10.1007\/s13311-022-01261-4_bib123","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/BF02716553","article-title":"Durable clinical benefit with exemestane in leptomeningeal metastasis of breast cancer","volume":"7","author":"Navarro Mart\u00edn","year":"2005","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib124","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1212\/WNL.55.1.117","article-title":"Response of leptomeningeal metastases from breast cancer to hormonal therapy","volume":"55","author":"Boogerd","year":"2000","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-022-01261-4_bib125","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/tbj.12554","article-title":"Endocrine therapy for leptomeningeal metastases from ER-positive breast cancer: case report and a review of the literature","volume":"22","author":"Zoghi","year":"2016","journal-title":"Breast J"},{"issue":"4","key":"10.1007\/s13311-022-01261-4_bib126","doi-asserted-by":"crossref","first-page":"CNS65","DOI":"10.2217\/cns-2020-0023","article-title":"Endocrine therapy for the treatment of leptomeningeal carcinomatosis in luminal breast cancer: a comprehensive review","volume":"9","author":"Fernandes","year":"2020","journal-title":"CNS Oncology"},{"issue":"9","key":"10.1007\/s13311-022-01261-4_bib127","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091242","article-title":"The PI3K\/AKT\/mTOR and CDK4\/6 pathways in endocrine resistant HR+\/HER2- metastatic breast cancer: biological mechanisms and new treatments.","volume":"11","author":"Presti","year":"2019","journal-title":"Cancers (Basel)."},{"issue":"32","key":"10.1007\/s13311-022-01261-4_bib128","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1007\/s13311-022-01261-4_bib129","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(21)00034-6","article-title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","volume":"22","author":"Rugo","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1007\/s13311-022-01261-4_bib130","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(19)30817-4","article-title":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial","volume":"21","author":"Jones","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1007\/s13311-022-01261-4_bib131","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor\u2013positive advanced breast cancer","volume":"366","author":"Baselga","year":"2011","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1007\/s13311-022-01261-4_bib132","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","article-title":"A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor\u2013positive breast cancer","volume":"26","author":"Tolaney","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1007\/s13311-022-01261-4_bib133","article-title":"Response of brain metastases from PIK3CA-mutant breast cancer to alpelisib.","volume":"4","author":"Batalini","year":"2020","journal-title":"JCO Precis Oncol."},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib134","doi-asserted-by":"crossref","first-page":"10784","DOI":"10.1038\/s41598-018-29062-w","article-title":"Buparlisib is a brain penetrable pan-PI3K inhibitor","volume":"8","author":"de Gooijer","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(17)30688-5","article-title":"Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Di Leo","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1007\/s13311-022-01261-4_bib136","doi-asserted-by":"crossref","first-page":"vi106","DOI":"10.1093\/annonc\/mdw367.13","article-title":"Phase II study of single agent buparlisib in recurrent\/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)","volume":"27","author":"Grommes","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1007\/s13311-022-01261-4_bib137","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10549-017-4596-7","article-title":"Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy","volume":"168","author":"Pistilli","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib138","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1186\/s12885-018-4371-0","article-title":"Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer","volume":"18","author":"Jin","year":"2018","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1007\/s13311-022-01261-4_bib139","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/annonc\/mdp407","article-title":"Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT)","volume":"21","author":"Niwi\u0144ska","year":"2010","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1007\/s13311-022-01261-4_bib140","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","article-title":"Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer","volume":"26","author":"Atchley","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1007\/s13311-022-01261-4_bib141","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3389\/fphar.2018.00909","article-title":"Association between BRCA status and triple-negative breast cancer: a meta-analysis","volume":"9","author":"Chen","year":"2018","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1007\/s13311-022-01261-4_bib142","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1007\/s13311-022-01261-4_bib143","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1007\/s13311-022-01261-4_bib144","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1200\/JCO.2021.39.15_suppl.1090","article-title":"Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician's choice of chemotherapy (PCT) in the phase 3 EMBRACA trial","volume":"39","author":"Litton","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1007\/s13311-022-01261-4_bib145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00012","article-title":"Significant clinical activity of olaparib in a somatic BRCA1-mutated triple-negative breast cancer with brain metastasis","volume":"3","author":"Pascual","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib146","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41523-019-0139-1","article-title":"Response to olaparib in a patient with germline BRCA2 mutation and breast cancer leptomeningeal carcinomatosis","volume":"5","author":"Exman","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"10.1007\/s13311-022-01261-4_bib147","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.gore.2016.10.004","article-title":"Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease","volume":"18","author":"Bangham","year":"2016","journal-title":"Gynecol Oncol Rep"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib148","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3892\/mco.2020.2035","article-title":"Long-term response to olaparib in carcinomatous meningitis of a BRCA2 mutated ovarian cancer: a case report","volume":"13","author":"Favier","year":"2020","journal-title":"Mol Clin Oncol"},{"issue":"12","key":"10.1007\/s13311-022-01261-4_bib149","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","article-title":"ANG1005, a brain-penetrating peptide\u2013drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases","volume":"26","author":"Kumthekar","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1007\/s13311-022-01261-4_bib150","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11060-007-9409-0","article-title":"Capecitabine therapy of central nervous system metastases from breast cancer","volume":"85","author":"Ekenel","year":"2007","journal-title":"J Neurooncol"},{"key":"10.1007\/s13311-022-01261-4_bib151","doi-asserted-by":"crossref","first-page":"208","DOI":"10.12659\/AJCR.901812","article-title":"Metronomic capecitabine effectively blocks leptomeningeal carcinomatosis from breast cancer: a case report and literature review","volume":"18","author":"Maur","year":"2017","journal-title":"Am J Case Rep"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib152","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1215\/S1152851703000334","article-title":"Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy","volume":"6","author":"Rogers","year":"2004","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1007\/s13311-022-01261-4_bib153","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3816\/CBC.2006.n.028","article-title":"Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report","volume":"7","author":"Tham","year":"2006","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"10.1007\/s13311-022-01261-4_bib154","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.1998.16.4.1561","article-title":"High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?","volume":"16","author":"Glantz","year":"1998","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1007\/s13311-022-01261-4_bib155","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0002-9610(78)90171-X","article-title":"Metastatic pattern of malignant melanoma: a study of 216 autopsy cases","volume":"135","author":"Patel","year":"1978","journal-title":"Am J Surg"},{"key":"10.1007\/s13311-022-01261-4_bib156","first-page":"579","article-title":"Intracranial metastases from systemic cancer","volume":"19","author":"Posner","year":"1978","journal-title":"Adv Neurol"},{"issue":"11","key":"10.1007\/s13311-022-01261-4_bib157","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1007\/s13311-022-01261-4_bib158","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1215\/15228517-2007-058","article-title":"Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features","volume":"10","author":"Raizer","year":"2008","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1007\/s13311-022-01261-4_bib159","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-009-9819-2","article-title":"Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma","volume":"94","author":"Groves","year":"2009","journal-title":"J Neurooncol"},{"issue":"7","key":"10.1007\/s13311-022-01261-4_bib160","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1007\/s13311-022-01261-4_bib161","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/cncr.32547","article-title":"Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: a case series","volume":"126","author":"Holbrook","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib162","first-page":"79","article-title":"Metastatic melanoma with leptomeningeal disease","volume":"12","author":"Marinova","year":"2021","journal-title":"J Adv Pract Oncol"},{"issue":"9","key":"10.1007\/s13311-022-01261-4_bib163","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1007\/s00415-012-6488-4","article-title":"Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab","volume":"259","author":"Bot","year":"2012","journal-title":"J Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib164","doi-asserted-by":"crossref","DOI":"10.36959\/885\/364","article-title":"Clincial response of central nervous system melanoma to anti-PD1 therapy in 2 melanoma patients.","volume":"1","author":"Glitza","year":"2017","journal-title":"Arch Immunol."},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib165","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/pcmr.12652","article-title":"Leptomeningeal melanoma\u2014a case series in the era of modern systemic therapy","volume":"31","author":"Arasaratnam","year":"2018","journal-title":"Pigment Cell Melanoma Res"},{"issue":"5","key":"10.1007\/s13311-022-01261-4_bib166","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1007\/s13311-022-01261-4_bib167","doi-asserted-by":"crossref","first-page":"10008","DOI":"10.1200\/JCO.2020.38.15_suppl.10008","article-title":"Single-center phase I\/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD)","volume":"38","author":"Glitza","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1007\/s13311-022-01261-4_bib168","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/2326-6066.CIR-15-0071","article-title":"Intrathecal administration of tumor-infiltrating lymphocytes is well tolerated in a patient with leptomeningeal disease from metastatic melanoma: a case report","volume":"3","author":"Glitza","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"3 Suppl","key":"10.1007\/s13311-022-01261-4_bib169","first-page":"917s","article-title":"Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma","volume":"7","author":"Clemons-Miller","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1007\/s13311-022-01261-4_bib170","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/CMR.0000000000000257","article-title":"Vemurafenib in leptomeningeal carcinomatosis from melanoma: a case report of near-complete response and prolonged survival","volume":"26","author":"Floudas","year":"2016","journal-title":"Melanoma Res"},{"issue":"3","key":"10.1007\/s13311-022-01261-4_bib171","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s11060-017-2472-2","article-title":"Rapid resolution of leptomeningeal disease with targeted therapy in a metastatic melanoma patient","volume":"133","author":"Glitza","year":"2017","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1007\/s13311-022-01261-4_bib172","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s12885-015-1391-x","article-title":"Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report","volume":"15","author":"Kim","year":"2015","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1007\/s13311-022-01261-4_bib173","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CMR.0b013e32835e589c","article-title":"Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report","volume":"23","author":"Lee","year":"2013","journal-title":"Melanoma Res"},{"issue":"11","key":"10.1007\/s13311-022-01261-4_bib174","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1200\/JCO.2012.46.5773","article-title":"Vemurafenib for leptomeningeal melanomatosis","volume":"31","author":"Sch\u00e4fer","year":"2013","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1007\/s13311-022-01261-4_bib175","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1200\/JCO.2013.48.7298","article-title":"Complete cytologic remission of V600E BRAF-mutant melanoma-associated leptomeningeal carcinomatosis upon treatment with dabrafenib","volume":"33","author":"Wilgenhof","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1007\/s13311-022-01261-4_bib176","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1124\/dmd.114.058339","article-title":"Factors influencing the CNS distribution of a novel MEK-1\/2 inhibitor: implications for combination therapy for melanoma brain metastases","volume":"42","author":"Vaidhyanathan","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1007\/s13311-022-01261-4_bib177","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/CMR.0000000000000162","article-title":"Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma","volume":"25","author":"Sakji-Dupr\u00e9","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1007\/s13311-022-01261-4_bib178","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.expneurol.2015.07.027","article-title":"A balanced view of the cerebrospinal fluid composition and functions: focus on adult humans","volume":"273","author":"Spector","year":"2015","journal-title":"Exp Neurol"},{"issue":"6501","key":"10.1007\/s13311-022-01261-4_bib179","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1126\/science.aaz2193","article-title":"Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"issue":"6","key":"10.1007\/s13311-022-01261-4_bib180","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1096-911X(20001201)35:6<716::AID-MPO51>3.0.CO;2-0","article-title":"Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8","volume":"35","author":"Kramer","year":"2000","journal-title":"Med Pediatr Oncol"},{"key":"10.1007\/s13311-022-01261-4_bib181","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00264","article-title":"B7H3 as a promoter of metastasis and promising therapeutic target.","volume":"8","author":"Dong","year":"2018","journal-title":"Front Oncol."},{"issue":"4","key":"10.1007\/s13311-022-01261-4_bib182","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/neuonc\/nos060","article-title":"Rhenium-186 liposomes as convection-enhanced nanoparticle brachytherapy for treatment of glioblastoma","volume":"14","author":"Phillips","year":"2012","journal-title":"Neuro Oncol"},{"issue":"Supplement_6","key":"10.1007\/s13311-022-01261-4_bib183","doi-asserted-by":"crossref","first-page":"vi65","DOI":"10.1093\/neuonc\/noab196.254","article-title":"CTNI-29. Safety and feasibility of rhenium-186 nanoliposome (186RNL) in recurrent glioma: the ReSPECT\u2122 phase 1 trial","volume":"23","author":"Brenner","year":"2021","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1007\/s13311-022-01261-4_bib184","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11912-018-0706-x","article-title":"The utility of liquid biopsy in central nervous system malignancies","volume":"20","author":"Nevel","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"10.1007\/s13311-022-01261-4_bib185","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/neuonc\/noz208","article-title":"A retrospective, quantitative assessment of disease burden in patients with leptomeningeal metastases from non-small-cell lung cancer","volume":"22","author":"Nevel","year":"2020","journal-title":"Neuro Oncol"},{"issue":"9","key":"10.1007\/s13311-022-01261-4_bib186","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/neuonc\/nox066","article-title":"Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors","volume":"19","author":"Lin","year":"2017","journal-title":"Neuro Oncol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01261-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01261-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923001332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923001332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01261-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:34:43Z","timestamp":1761806083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923001332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":186,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1878747923001332"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01261-4","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leptomeningeal Metastases: New Opportunities in the Modern Era","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01261-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The Author(s). Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}